Low‐dose suramin in autism spectrum disorder: a small, phase I/II, randomized clinical trial

No drug is yet approved to treat the core symptoms of autism spectrum disorder (ASD). Low-dose suramin was effective in the maternal immune activation and Fragile X mouse models of ASD. The Suramin Autism Treatment-1 (SAT-1) trial was a double-blind, placebo-controlled, translational pilot study to examine the safety and activity of low-dose suramin in children with ASD.Ten male subjects with ASD, ages 5-14 years, were matched by age, IQ, and...